The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy
Authors
Keywords
-
Journal
Expert Review of Anticancer Therapy
Volume 16, Issue 7, Pages 697-703
Publisher
Informa UK Limited
Online
2016-05-25
DOI
10.1080/14737140.2016.1192471
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
- (2016) Andrea Wang-Gillam et al. LANCET
- PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer
- (2016) Benoist Chibaudel et al. Cancer Medicine
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients
- (2015) T. C. Chang et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy
- (2015) Elena De Mattia et al. DRUG RESISTANCE UPDATES
- Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update
- (2015) Thomas J. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients
- (2015) Sylvia Chen et al. Pharmacogenetics and Genomics
- A novel UGT1 marker associated with better tolerance against irinotecan-induced severe neutropenia in metastatic colorectal cancer patients
- (2015) S Chen et al. PHARMACOGENOMICS JOURNAL
- Clinical Implication of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Combined with FOLFIRI in the First-line Setting
- (2015) Chien-Yu Lu et al. Translational Oncology
- UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians
- (2014) Lei Cheng et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Preclinical Activity of Nanoliposomal Irinotecan Is Governed by Tumor Deposition and Intratumor Prodrug Conversion
- (2014) A. V. Kalra et al. CANCER RESEARCH
- Dose-Finding and Pharmacokinetic Study to Optimize the Dosing of Irinotecan According to theUGT1A1Genotype of Patients With Cancer
- (2014) Federico Innocenti et al. JOURNAL OF CLINICAL ONCOLOGY
- Irinotecan Pharmacogenetics: A Finished Puzzle?
- (2014) Mitch A. Phelps et al. JOURNAL OF CLINICAL ONCOLOGY
- Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial
- (2014) Helmut Oettle et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma†
- (2013) A. C. Roy et al. ANNALS OF ONCOLOGY
- A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer
- (2013) A H Ko et al. BRITISH JOURNAL OF CANCER
- Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer
- (2013) Lucía Cortejoso et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai
- (2013) Xun Cai et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- OATP1A/1B Transporters Affect Irinotecan and SN-38 Pharmacokinetics and Carboxylesterase Expression in Knockout and Humanized Transgenic Mice
- (2013) D. Iusuf et al. MOLECULAR CANCER THERAPEUTICS
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians
- (2013) X Liu et al. PHARMACOGENOMICS JOURNAL
- Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group
- (2011) Uwe Pelzer et al. EUROPEAN JOURNAL OF CANCER
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer
- (2010) B Glimelius et al. PHARMACOGENOMICS JOURNAL
- UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients
- (2009) Masahide Onoue et al. International Journal of Clinical Oncology
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now